Procalcitonin As an Additional Marker for The Diagnosis Of Metabolic Syndrome, Case-Control Study Ata Tertiary Care Centre, Tamaka, Kola

Background Metabolic syndrome (MS) is a clustering of metabolic risk factors namely abdominal obesity, hypertension, hyperglycemia, high serum triglyceride levels and low serum HDL.  Procalcitonin is a polypeptide precursor of hormone calcitonin that is released in response to systemic inflammation not only by neuroendocrine cells of the lungs, intestine, and thyroid (C cells), but also by adipose tissue. Therefore, plasma procalcitonin can serve as a potential biomarker for detection of obesity related low-grade inflammation even in the very early stages, thereby increasing the sensitivity and specificity. Material and Methods Patients admitted with diagnosis of metabolic syndrome at RL Jalappa Hospital and Research Centre, Kolar were selected and results of waist circumference, SBP, DBP, TG, cholesterol, HDL, LDL, VLDL, FBS, Plasma procalcitonin will be correlated in two different groups separately. Results Mean Procalcitonin level in the case group was seen to be 1.806±1.236 ng/dl and among the controls was seen to be 0.163±0.1613 ng/dl. This difference in the Procalcitonin level was statistically significant (p < .001). We also found that the Procalcitonin levels had significant association with Waist circumference, Triglycrides, HDL & FBS values with a p value < .001. Area under the ROC for Procalcitonin as a diagnostic test was found to be 0.942 which indicates that it has an excellent prediction value (p< .001). At 0.013 cut off value, we found that Procalcitonin has a sensitivity of 97% and a specificity of 87.9%. Conclusion This study suggests a positive correlation between elevated PCT levels and MetS, integrating PCT into the diagnostic framework for MetS could improve early detection, risk stratification, and monitoring of treatment efficacy, ultimately enhancing patient outcomes. However, practical challenges related to specificity, standardization, cost, and clinical integration must be addressed to realize its full potential.

Authors

Publication Details

Journal
African Journal of Biomedical Research
Published
2024-12-23
DOI
https://doi.org/10.53555/ajbr.v27i4s.5354
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Procalcitonin As an Additional Marker for The Diagnosis Of Metabolic Syndrome, Case-Control Study Ata Tertiary Care Centre, Tamaka, Kola

Dr Rupa kasaraneni
African Journal of Biomedical Research
Liver Disease Diagnosis and Treatment
article

Procalcitonin As an Additional Marker for The Diagnosis Of Metabolic Syndrome, Case-Control Study Ata Tertiary Care Centre, Tamaka, Kola

Dr Rupa kasaraneni
article en

Abstract

Background Metabolic syndrome (MS) is a clustering of metabolic risk factors namely abdominal obesity, hypertension, hyperglycemia, high serum triglyceride levels and low serum HDL.  Procalcitonin is a polypeptide precursor of hormone calcitonin that is released in response to systemic inflammation not only by neuroendocrine cells of the lungs, intestine, and thyroid (C cells), but also by adipose tissue. Therefore, plasma procalcitonin can serve as a potential biomarker for detection of obesity related low-grade inflammation even in the very early stages, thereby increasing the sensitivity and specificity. Material and Methods Patients admitted with diagnosis of metabolic syndrome at RL Jalappa Hospital and Research Centre, Kolar were selected and results of waist circumference, SBP, DBP, TG, cholesterol, HDL, LDL, VLDL, FBS, Plasma procalcitonin will be correlated in two different groups separately. Results Mean Procalcitonin level in the case group was seen to be 1.806±1.236 ng/dl and among the controls was seen to be 0.163±0.1613 ng/dl. This difference in the Procalcitonin level was statistically significant (p < .001). We also found that the Procalcitonin levels had significant association with Waist circumference, Triglycrides, HDL & FBS values with a p value < .001. Area under the ROC for Procalcitonin as a diagnostic test was found to be 0.942 which indicates that it has an excellent prediction value (p< .001). At 0.013 cut off value, we found that Procalcitonin has a sensitivity of 97% and a specificity of 87.9%. Conclusion This study suggests a positive correlation between elevated PCT levels and MetS, integrating PCT into the diagnostic framework for MetS could improve early detection, risk stratification, and monitoring of treatment efficacy, ultimately enhancing patient outcomes. However, practical challenges related to specificity, standardization, cost, and clinical integration must be addressed to realize its full potential.

African Journal of Biomedical Research
Good health and well-being
Openalex Percentile: Top 64%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Procalcitonin As an Additional Marker for The Diagnosis Of Metabolic Syndrome, Case-Control Study Ata Tertiary Care Centre, Tamaka, Kola — Dr Rupa kasaraneni · African Journal of Biomedical Research (2024) | TGRS Research Map | TGRS